A Systematic Review of Health Economic Evaluation on Targeted Therapies for First-Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Quality Evaluation
Article in Cancer Management and Research (June 2020)
The most recent citing publications are shown below. View all 20 publications that cite this research output on Dimensions.
A systematic review of pharmacoeconomic evaluations of erlotinib in the first-line treatment of advanced non-small cell lung cancer
Article in The European Journal of Health Economics (March 2019)
Approaches to Capturing Value in Oncology
Book chapter (December 2018)